Inovio Biomedical Corporation (AMEX: INO) announced today additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE